The efficacy of desvenlafaxine for improving functioning and quality of life measures in patients with major depressive disorder

被引：0
|
作者：
Soares, C.
Thase, M. [1 ]
Kornstein, S. [2 ]
Brisard, C. [3 ]
Septien-Velez, L. [3 ]
Germain, J. M. [3 ]
Pitrosky, B. [3 ]
Patroneva, A. [4 ]
Jiang, Q. [4 ]
Ninan, P. [4 ]
Ganguly, R. [4 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[3] Wyeth Ayerst Res, Paris, France
[4] Wyeth Ayerst Res, Collegeville, PA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2008年 / 18卷
关键词：
D O I：
10.1016/S0924-977X(08)70478-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S342 / S343
页数：2
相关论文
共 50 条
  • [21] Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder
    Slyepchenko, Anastasiya
    Allega, Olivia R.
    Leng, Xiamin
    Minuzzi, Luciano
    Eltayebani, Maha M.
    Skelly, Matthew
    Sassi, Roberto B.
    Soares, Claudio N.
    Kennedy, Sidney H.
    Frey, Benicio N.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 (07): : 683 - 696
  • [22] Desvenlafaxine succinate for the treatment of major depressive disorder
    Lohoff, Falk W.
    Rickels, Karl
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (12) : 2129 - 2136
  • [23] The role of dopaminergic agents in improving quality of life in major depressive disorder
    Waguih William IsHak
    Michael Davis
    Jessica Jeffrey
    Konstantin Balayan
    Robert N. Pechnick
    Kara Bagot
    Mark Hyman Rapaport
    Current Psychiatry Reports, 2009, 11 : 503 - 508
  • [24] The Role of Dopaminergic Agents in Improving Quality of Life in Major Depressive Disorder
    IsHak, Waguih William
    Davis, Michael
    Jeffrey, Jessica
    Balayan, Konstantin
    Pechnick, Robert N.
    Bagot, Kara
    Rapaport, Mark Hyman
    CURRENT PSYCHIATRY REPORTS, 2009, 11 (06) : 503 - 508
  • [25] Quality of life in major depressive disorder
    Guermazi, A.
    Smaoui, N.
    Omri, S.
    Lajmi, I.
    Feki, R.
    Bouali, M. Maalej
    Charfi, N.
    Zouari, N.
    Ben Thabet, J.
    Zouari, L.
    Maalej, M.
    EUROPEAN PSYCHIATRY, 2020, 63 : S374 - S374
  • [26] Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline
    Mosca, Daniel
    Zhang, Min
    Prieto, Rita
    Boucher, Matthieu
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (02) : 182 - 192
  • [27] Impact of early-life traumatic experiences on objective measures of executive functioning in patients with major depressive disorder
    Berdzenishvili, E.
    Chkonia, E.
    Matchavariani, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S171 - S171
  • [28] Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline
    Prieto, R.
    Mosca, D.
    Zhang, M.
    Boucher, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S456 - S456
  • [29] Study of Life Events and Quality of Life in Patients of Major Depressive Disorder
    Patil, Alkesh
    Sengupta, Aparna
    Mule, Ashwini
    Karia, Sagar
    ANNALS OF INDIAN PSYCHIATRY, 2025, 9 (01) : 75 - 80
  • [30] Predicting Functioning and Quality of Life Using Objective and Subjective Measures of Sleep and Biological Rhythms in Major Depressive and Bipolar Disorder
    Slyepchenko, Anastasiya
    Allega, Olivia
    Leng, Xiamin
    Minuzzi, Luciano
    Eltayebani, Maha M.
    Skelly, Matthew
    Sassi, Roberto
    Soares, Claudio
    Kennedy, Sidney
    Frey, Benicio N.
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S166 - S166
12345